- Home
- GWRS vs SCPH Comparison
GWRS vs SCPH Comparison
Compare GWRS & SCPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GWRS
- SCPH
- Stock Information
- Founded
- GWRS 2003
- SCPH 2013
- Country
- GWRS United States
- SCPH United States
- Employees
- GWRS N/A
- SCPH N/A
- Industry
- GWRS Water Supply
- SCPH Biotechnology: Pharmaceutical Preparations
- Sector
- GWRS Utilities
- SCPH Health Care
- Exchange
- GWRS Nasdaq
- SCPH Nasdaq
- Market Cap
- GWRS 286.0M
- SCPH 173.6M
- IPO Year
- GWRS 2010
- SCPH 2017
- Fundamental
- Price
- GWRS $10.21
- SCPH $3.97
- Analyst Decision
- GWRS
- SCPH Strong Buy
- Analyst Count
- GWRS 0
- SCPH 3
- Target Price
- GWRS N/A
- SCPH $14.00
- AVG Volume (30 Days)
- GWRS 51.1K
- SCPH 289.9K
- Earning Date
- GWRS 08-06-2025
- SCPH 08-13-2025
- Dividend Yield
- GWRS 2.99%
- SCPH N/A
- EPS Growth
- GWRS N/A
- SCPH N/A
- EPS
- GWRS 0.23
- SCPH N/A
- Revenue
- GWRS $53,539,000.00
- SCPH $41,982,000.00
- Revenue This Year
- GWRS $8.31
- SCPH $108.95
- Revenue Next Year
- GWRS $6.52
- SCPH $73.83
- P/E Ratio
- GWRS $44.21
- SCPH N/A
- Revenue Growth
- GWRS 3.94
- SCPH 138.10
- 52 Week Low
- GWRS $9.37
- SCPH $1.94
- 52 Week High
- GWRS $13.98
- SCPH $5.65
- Technical
- Relative Strength Index (RSI)
- GWRS 45.02
- SCPH 61.96
- Support Level
- GWRS $10.05
- SCPH $3.77
- Resistance Level
- GWRS $10.59
- SCPH $4.08
- Average True Range (ATR)
- GWRS 0.27
- SCPH 0.17
- MACD
- GWRS -0.03
- SCPH -0.04
- Stochastic Oscillator
- GWRS 15.54
- SCPH 76.92
About GWRS Global Water Resources Inc.
Global Water Resources Inc operates as a water resources management company that owns, operates, and manages water, wastewater, and recycled water utilities in strategically located communities, principally in metropolitan Phoenix, Arizona. It operates within the State of Arizona.
About SCPH scPharmaceuticals Inc.
scPharmaceuticals Inc is a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care and reduce healthcare costs. The company's main product is Furoscix. Furoscix consists of this patented formulation of furosemide for subcutaneous administration with wearable, portable sc2Wear Infusor for the treatment of edema in patients with heart failure.